Neuberger Berman Group LLC - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 60 filers reported holding FATE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Neuberger Berman Group LLC ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2022$8,442,000
-9.6%
376,683
-0.1%
0.01%0.0%
Q2 2022$9,341,000
-32.7%
376,949
+5.2%
0.01%
-25.0%
Q1 2022$13,887,000
-32.5%
358,192
+1.7%
0.01%
-25.0%
Q4 2021$20,560,000
-9.3%
352,336
-8.5%
0.02%
-20.0%
Q3 2021$22,676,000
+0.4%
385,187
+48.0%
0.02%0.0%
Q2 2021$22,583,000
+386.4%
260,293
+359.2%
0.02%
+400.0%
Q1 2021$4,643,000
-16.3%
56,683
-7.1%
0.00%
-33.3%
Q4 2020$5,547,000
+127.5%
61,0000.0%0.01%
+100.0%
Q3 2020$2,438,000
+92.1%
61,000
+64.9%
0.00%
+50.0%
Q2 2020$1,269,000
+54.4%
37,0000.0%0.00%
+100.0%
Q1 2020$822,000
-53.3%
37,000
-58.9%
0.00%
-50.0%
Q4 2019$1,761,000
+5.6%
90,000
-16.2%
0.00%0.0%
Q3 2019$1,668,000
-14.4%
107,400
+11.9%
0.00%0.0%
Q2 2019$1,949,000
+84.9%
96,000
+60.0%
0.00%
+100.0%
Q1 2019$1,054,000
+36.9%
60,0000.0%0.00%0.0%
Q4 2018$770,000
-60.6%
60,000
-50.0%
0.00%
-50.0%
Q3 2018$1,955,000
+1050.0%
120,000
+700.0%
0.00%
Q2 2018$170,000
-88.6%
15,000
-90.2%
0.00%
-100.0%
Q1 2018$1,496,000
+41.3%
153,250
-11.5%
0.00%
+100.0%
Q4 2017$1,059,000
+100.9%
173,250
+30.3%
0.00%0.0%
Q3 2017$527,000
+227.3%
133,000
+167.6%
0.00%
Q2 2017$161,000
-48.4%
49,700
-27.6%
0.00%
Q1 2017$312,00068,6000.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q2 2017
NameSharesValueWeighting ↓
ARCH Venture Management, LLC 716,392$11,126,00012.18%
Polaris Venture Management Co. V, L.L.C. 1,139,783$17,701,00010.06%
Grosvenor Holdings, L.L.C. 2,285,714$35,497,0006.41%
Redmile Group, LLC 11,216,809$174,197,0005.83%
Casdin Capital, LLC 2,550,000$39,601,500,0004.10%
DAFNA Capital Management LLC 470,000$7,299,0002.74%
Ghost Tree Capital, LLC 350,000$5,436,0001.38%
Artal Group S.A. 2,000,000$31,060,0001.24%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 1,952,897$30,328,0001.24%
Copernicus Capital Management, LLC 75,000$1,165,0001.08%
View complete list of FATE THERAPEUTICS INC shareholders